<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

Investival 2022 Webinar How to navigate your late-stage biotech fundraising

How to navigate your late-stage biotech fundraising in the current economic climate

Watch now

Join us to learn how the current economic and political situations have impacted the biotech fundraising landscape and hear from experts how to best prepare your company to strive on the short/medium term.

  • How has the present market headwinds changed later stage Biotech fundraising?
  • Considerations in the present market for Series A / B companies from a fundraising perspective.
  • What financing alternatives exist?
  • What is the view of the growth stage biotech VC investors

Moderator: Ross Johnson, Managing Director, DFIN
Robbie McLaren
, Partner, Latham & Watkins
Jennifer Gascoyne
, Partner, Latham & Watkins
Hsin Loke
, VP of Finance & Operations, OMass Therapeutics (Series B $100K)
Gil Bar-Nahum
, Managing Director, Jefferies International

Ross Johnson      Robbie McLaren, Partner, Latham & Watkins      Jennifer Gascoyne, General Partners, Latham & Watkins      Hsin Loke, VP of Finance and Operations, OMass Therapeutics      gil bar nahum

DFIN 300x150DFIN is a leading global risk and compliance solutions company. We provide domain expertise, enterprise software and data analytics for every stage of our clients' business and investment lifecycles. Markets fluctuate, regulations evolve, technology advances, and through it all, DFIN delivers confidence with the right solutions in moments that matter.



Watch now